Alcon Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Alcon şirketinin toplam hissedar öz sermayesi $21.4B ve toplam borcu $4.7B olup, bu da borç-öz sermaye oranını 21.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $30.4B ve $9.0B dir. Alcon 'in FAVÖK'ü $1.2B faiz karşılama oranı 8.3 dur. Şirketin $2.0B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

21.9%

Borç/özkaynak oranı

US$4.69b

Borç

Faiz karşılama oranı	8.3x
Nakit	US$1.99b
Eşitlik	US$21.39b
Toplam yükümlülükler	US$8.97b
Toplam varlıklar	US$30.36b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0A0D 'nin kısa vadeli varlıkları ( $6.3B ) kısa vadeli yükümlülüklerini ( $2.5B ) aşıyor.

Uzun Vadeli Yükümlülükler: 0A0D 'un kısa vadeli varlıkları ( $6.3B ) uzun vadeli yükümlülüklerini ( $6.5B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0A0D 'nin net borç/öz sermaye oranı ( 12.6% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 0A0D şirketinin borç/öz sermaye oranı son 5 yılda 17.9% seviyesinden 21.9% seviyesine yükseldi.

Borç Kapsamı: 0A0D 'nin borcu işletme nakit akışı ( 44.1% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 0A0D 'in borcuna ilişkin faiz ödemeleri EBIT ( 8.3 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Alcon Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: EPS: US$0.53 (vs US$0.41 in 3Q 2023)

Alcon Inc. Revises Earnings Guidance for the Year 2024

Alcon Announces the U.S. Launch of PRECISION®, the Only One-Week Replacement Contact Lens

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: US$0.45 (vs US$0.34 in 2Q 2023)

Alcon Inc. Maintains Earnings Guidance for the Year 2024

Now 22% undervalued

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

First quarter 2024 earnings released: EPS: US$0.50 (vs US$0.35 in 1Q 2023)

Upcoming dividend of CHF0.24 per share

Alcon Inc. Approves Gross Dividend

Now 20% undervalued

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Dividend of CHF0.24 announced

Alcon Announces Management Changes

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings released: EPS: US$1.98 (vs US$0.68 in FY 2022)

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.41 (vs US$0.24 in 3Q 2022)

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

First quarter 2023 earnings released: EPS: US$0.35 (vs US$0.34 in 1Q 2022)

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.21 per share at 0.3% yield

Full year 2022 earnings released: EPS: US$0.68 (vs US$0.77 in FY 2021)

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Now 20% undervalued after recent price drop

Alcon Inc. Updates Earnings Guidance for the Year 2022

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Second quarter 2022 earnings released: EPS: US$0.30 (vs US$0.31 in 2Q 2021)

Alcon Inc. Revises Revenue Guidance for 2022

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

Alcon Inc. Reaffirms Earnings Guidance for the Fiscal 2022

First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.17 in 1Q 2021)

Alcon Inc. Declares Dividend for 2021

Insufficient new directors

Alcon Announces Key Data to Be Presented at This Year’s American Society of Cataract and Refractive Surgery Meeting on its SMART Solutions for Cataract Surgery

Alcon Inc. Announces Launch of Clareon Portfolio in the U.S

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Alcon Inc. Proposes Dividend

Alcon Inc. Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe

Alcon Continues Its Successful Rollout of Precision1 Daily Disposable Contact Lenses, Now Available in Key Markets Throughout Latin America, Asia & Europe

Third quarter 2021 earnings released: EPS US$0.004 (vs US$0.30 loss in 3Q 2020)

President of Global Business & Innovation Michael Onuscheck has left the company

Second quarter 2021 earnings released: EPS US$0.31 (vs US$0.86 loss in 2Q 2020)

Alcon to Launch TOTAL30 as the First-and-Only Monthly Replacement, Water Gradient Contact Lens

First quarter 2021 earnings released: EPS US$0.17 (vs US$0.12 loss in 1Q 2020)

Alcon Inc. Provides Earnings Guidance for the Full Year 2021

Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S

Full year 2020 earnings released: US$1.09 loss per share (vs US$1.34 loss in FY 2019)

Revenue beats expectations

Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S

Alcon Launches PRECISION1 for Astigmatism Contact Lenses in the U.S

Alcon Inc. Announces Launch of AcrySof IQ Vivity, the First and Only Non-Diffractive Extended Depth of Focus Intraocular Lens in the U.S

Alcon Inc., Annual General Meeting, Apr 28, 2021

Alcon Canada Introduces AcrySof IQ Vivity, the Only Presbyopia-Correcting Intraocular Lens with X-WAVE Technology

Alcon Inc. Unable to Provide an Estimate for Financial Results for the Full Year 2020

Alcon Announces Continued Momentum of its PRECISION1® One-Day, Silicone Hydrogel (SiHy) Contact Lenses

Alcon, Inc. acquired Tear Film Innovations Inc. for approximately $150 million.

Alcon Inc. Provides No Financial Guidance for the Year 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi